Dr. Reddy’s Laboratories has announced key leadership and governance updates following its recent Board meeting held on May 12, 2026. The company has confirmed the re-appointment of an Independent Director, the appointment of a new Independent Director, and the induction of a new Statutory Auditor. Additionally, Mr. Sandeep Khandelwal has been elevated to the role of Senior Management Personnel, reflecting the company’s focus on its strategic growth and leadership development.
Strengthening Board Governance
The company has reinforced its board structure with two significant appointments. Dr. K P Krishnan has been re-appointed as an Independent Director for a second five-year term, effective from January 7, 2027, through January 6, 2032. Furthermore, Mr. Srikanth Velamakanni has been appointed as an Additional Director, categorized as an Independent Director. His term is set for five consecutive years, starting July 1, 2026, and running until June 30, 2031.
Strategic Leadership Elevation
As part of its organizational development, Mr. Sandeep Khandelwal, the Global Generics India Head, has been elevated to the position of Senior Management Personnel, effective May 12, 2026. Mr. Khandelwal, who has been instrumental in the transformation of the company’s India business, will also join the Management Council. His leadership has seen the India segment’s revenue grow from Rs 2,300 crore to Rs 7,000 crore over the last seven years, with significant margin expansion.
Auditor Appointments
The company has updated its audit oversight. M/s Deloitte Haskins & Sells, LLP has been appointed as the new Statutory Auditors for a five-year term, covering the period from the conclusion of the 42nd Annual General Meeting (AGM) through the conclusion of the 47th AGM. Additionally, M/s Sagar & Associates has been re-appointed as the Cost Auditors for the Financial Year 2026-27.
Source: BSE
